Literature DB >> 30811949

Changing Prevalence of Lower Airway Infections in Young Children with Cystic Fibrosis.

Oded Breuer1,2, Andre Schultz1,3,2, Lidija Turkovic1, Nicholas de Klerk1, Anthony D Keil2,4, Siobhain Brennan1, Joanne Harrison5,6,7, Colin Robertson5,6,7, Philip J Robinson5,6,7, Peter D Sly8, Sarath Ranganathan5,6,7, Stephen M Stick1,3,2, Daan Caudri1,2,9.   

Abstract

Rationale: Historical studies suggest that airway infection in cystic fibrosis initiates with Staphylococcus aureus and Haemophilus influenzae, with later emergence of Pseudomonas aeruginosa. Aspergillus species are regarded as relatively infrequent, late-occurring infections.
Objectives: To assess the prevalence and change in prevalence of early lower airway infections in a modern cohort of children with cystic fibrosis.
Methods: All infants diagnosed with cystic fibrosis after newborn screening participating in the Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF) cohort study between 2000 and 2018 were included. Participants prospectively underwent BAL at 3-6 months, 1 year, and annually up to 6 years of age. Lower airway infection prevalence was described. Changes in prevalence patterns were assessed longitudinally using generalized estimating equations controlling for age and repeated visits.Measurements and Main
Results: A total of 380 infants underwent 1,759 BALs. The overall prevalence and median age of first acquisition of the most common infections were as follows: S. aureus, 11%, 2.5 years; P. aeruginosa, 8%, 2.4 years; Aspergillus species, 11%, 3.2 years; and H. influenzae, 9%, 3.1 years. During the study, a significant decrease in prevalence of P. aeruginosa (P < 0.001) and S. aureus (P < 0.001) was observed with a significant change toward more aggressive treatment. Prevalence of Aspergillus infections did not significantly change (P = 0.669).Conclusions: Aspergillus species and P. aeruginosa are commonly present in the lower airways from infancy. The decrease in prevalence of P. aeruginosa and S. aureus since 2000, coinciding with a more aggressive therapeutic approach, has resulted in Aspergillus becoming the most commonly isolated pathogen in young children. Further research is warranted to understand the implication of these findings.

Entities:  

Keywords:  BAL

Mesh:

Year:  2019        PMID: 30811949     DOI: 10.1164/rccm.201810-1919OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  18 in total

1.  Selective Sampling of the Lower Airway in Children with Cystic Fibrosis: What Are We Missing?

Authors:  Andrew Turnbull; Dominic Hughes; Jane Davies
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

2.  The immunomodulatory effects of vitamin D drops in children with recurrent respiratory tract infections.

Authors:  Jianqiu Xiao; Wei He
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

Review 3.  Progress and challenges in fungal lung disease in cystic fibrosis.

Authors:  Gina Hong
Journal:  Curr Opin Pulm Med       Date:  2022-09-19       Impact factor: 2.868

4.  Clinical Impact of Aspergillus fumigatus in Children with Cystic Fibrosis.

Authors:  Valentina Fainardi; Chiara Sodini; Michela Deolmi; Andrea Ciuni; Kaltra Skenderaj; Maria Bice Stabile; Cosimo Neglia; Elena Mariotti Zani; Cinzia Spaggiari; Nicola Sverzellati; Susanna Esposito; Giovanna Pisi
Journal:  Microorganisms       Date:  2022-03-29

Review 5.  The Airway Microbiome-IL-17 Axis: a Critical Regulator of Chronic Inflammatory Disease.

Authors:  Jenny M Mannion; Rachel M McLoughlin; Stephen J Lalor
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-11       Impact factor: 8.667

6.  A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis.

Authors:  Daan Caudri; Lidija Turkovic; Nicholas H de Klerk; Tim Rosenow; Conor P Murray; Ewout W Steyerberg; Sarath C Ranganathan; Peter Sly; Stephen M Stick; Oded Breuer
Journal:  Pediatr Pulmonol       Date:  2021-10-12

7.  Shifting Landscape of Airway Infection in Early Cystic Fibrosis.

Authors:  Jordana E Hoppe; Scott D Sagel
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

Review 8.  Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity.

Authors:  Daniel R Laucirica; Luke W Garratt; Anthony Kicic
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

9.  CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes.

Authors:  Alexander J Currie; Ellen T Main; Heather M Wilson; Darius Armstrong-James; Adilia Warris
Journal:  Front Cell Infect Microbiol       Date:  2020-07-24       Impact factor: 5.293

10.  Early Aspergillosis in Cystic Fibrosis and Air Trapping: Guilt by Association?

Authors:  Dave P Nichols; Richard B Moss
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.